Funding boost will take Lead Program Inhibitor forward

Pre-clinical biotech BiPER Therapeutics, (Strasbourg) a developer of first-in-class drug candidates targeting BiP protein to treat gastrointestinal cancers has raised a total of €1. Click to read more...

Related Keywords

France ,French ,Wiclub Sant ,Guillaume Vetter Genoud ,Cyril Ronco ,Stephane Rocchi ,Rachid Benhida ,Mehdi Chelbi ,Zaki Sellam , ,Grand Est ,Clinical Trial Application ,Investigational New Drug ,Endoplasmic Reticulum ,Landmark Bioventure ,Morgan Rapinat ,Cancer ,Viper ,Funding ,Linical ,Herapeutics ,Drug ,Gastrointestinal ,Need ,Company ,Purok ,